Assess the Immunogenicity of 3 Doses of Pediarix®, Prevnar® & ActHIB® Given to Healthy Infants When Administered With GSK Biologicals' 2 Dose Oral Live Attenuated Human Rotavirus Vaccine Given During the Same Vaccination Visit or Separately

Trial Profile

Assess the Immunogenicity of 3 Doses of Pediarix®, Prevnar® & ActHIB® Given to Healthy Infants When Administered With GSK Biologicals' 2 Dose Oral Live Attenuated Human Rotavirus Vaccine Given During the Same Vaccination Visit or Separately

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs RIX 4414 (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Hib vaccine conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Gastroenteritis; Haemophilus infections; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Feb 2012 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
    • 01 Nov 2008 Results published in Pediatrics.
    • 02 Feb 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top